A gene expression database for the molecular pharmacology of cancer

Cluster analysis and display of genome-wide expression patterns

1998 • 16,410 citations

Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray

1995 • 9,575 citations

Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines

1991 • 3,158 citations

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

1988 • 3,038 citations

A Leisurely Look at the Bootstrap, the Jackknife, and Cross-Validation

1983 • 2,903 citations

Exploring the new world of the genome with DNA microarrays

1999 • 2,454 citations

Systematic variation in gene expression patterns in human cancer cell lines

2000 • 2,119 citations

Use of a cDNA microarray to analyse gene expression patterns in human cancer

1996 • 2,002 citations

Parallel human genome analysis: microarray-based expression monitoring of 1000 genes.

1996 • 1,629 citations

Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen

1995 • 1,489 citations

An Information-Intensive Approach to the Molecular Pharmacology of Cancer

1997 • 1,177 citations

A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization.

1996 • 1,146 citations

Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm

1989 • 943 citations

Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

1997 • 872 citations

DNA Topoisomerases: Essential Enzymes and Lethal Targets

1994 • 722 citations

The National Cancer Institute: cancer drug discovery and development program.

1992 • 699 citations

Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes

1999 • 340 citations

Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

1994 • 334 citations

Neural Computing in Cancer Drug Development: Predicting Mechanism of Action

1992 • 301 citations

MedMiner: An Internet Text-Mining Tool for Biomedical Information, with Application to Gene Expression Profiling

1999 • 259 citations

Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval

2004 • 241 citations

Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.

1995 • 215 citations

Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines

1996 • 214 citations

The NCI In Vitro Anticancer Drug Discovery Screen

1997 • 195 citations

The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.

1997 • 168 citations

L-Asparaginase and L-Asparagine Metabolism

1970 • 160 citations

Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.

1992 • 156 citations

Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen.

1992 • 119 citations

Identification of Epidermal Growth Factor Receptor and c-erbB2 Pathway Inhibitors by Correlation With Gene Expression Patterns

1997 • 116 citations

Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines.

1998 • 113 citations

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours

1998 • 107 citations

Mining the NCI Anticancer Drug Discovery Databases: Genetic Function Approximation for the QSAR Study of Anticancer Ellipticine Analogues

1998 • 105 citations

L-Asparaginase

1970 • 96 citations

A protein expression database for the molecular pharmacology of cancer

1997 • 85 citations

Cancer Therapeutics: Experimental And Clinical Agents

1997 • 84 citations

Use of the Kohonen Self-organizing Map to Study the Mechanisms of Action of Chemotherapeutic Agents

1994 • 83 citations

Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes.

1996 • 79 citations

Mining the National Cancer Institute Anticancer Drug Discovery Database: Cluster Analysis of Ellipticine Analogs with p53-Inverse and Central Nervous System-Selective Patterns of Activity

1998 • 78 citations

Mechanisms of Topoisomerase I Inhibition by Anticancer Drugs

1994 • 77 citations

Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's drug discovery program for cancer and AIDS

1994 • 71 citations

Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.

1995 • 61 citations

Antitumor Enzyme: Polyethylene Glycol–modified Asparaginase

1990 • 57 citations

DNA Topoisomerase II Inhibitors

1997 • 50 citations

Molecular targets in the National Cancer Institute drug screen

1995 • 46 citations

Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines

1997 • 33 citations

Mapping Drug Interactions at the Covalent Topoisomerase II-DNA Complex by Bisantrene/Amsacrine Congeners

1998 • 30 citations

Cancer chemotherapeutic agents

1981 • 12 citations

Reversal of multidrug resistance.

1994 • 5 citations